Pharmaceutical Company Research Grants (Investigator-Initiated Studies)

Pharmaceutical and biopharmaceutical companies fund external research in two structurally different ways, and conflating them is one of the more common category errors in research administration. The first is sponsorship: the company designs the protocol, holds the Investigational New Drug (IND) or Investigational Device Exemption (IDE) application, and directs the study, typically executing it through a Clinical Research Organization (CRO) — see Sponsor vs. CRO for how that division of labor is structured. The second is the investigator-initiated study (IIS), sometimes called an investigator-sponsored study (ISS) or externally sponsored research grant: an independent investigator conceives the research question, writes the protocol, and — if the company funds it — remains the study’s sponsor-investigator of record, holding the IND/IDE (or operating under an exemption) and controlling the science, while the company’s involvement is limited to reviewing the proposal for scientific merit and strategic fit, approving funding, and, where the study involves the company’s product, supplying drug, device, or placebo under the terms of the grant agreement.

This distinction matters administratively because it changes who bears regulatory and contractual responsibility. In an IIS, the investigator’s institution — not the pharmaceutical company — is typically the IRB’s point of contact, holds the regulatory filing, and is accountable for protocol conduct and data integrity, even though the company is the funder. See sponsor-investigator for the regulatory role this creates under ICH E6(R2) and FDA regulations. That allocation of control is also what separates an IIS grant from a routine unrestricted educational grant: an IIS grant funds a specific, investigator-designed research protocol with defined deliverables, whereas an unrestricted educational or CME grant funds broader activity (a symposium, a training program) without funding a specific study.

Operational definition

A funding arrangement qualifies as a pharmaceutical company research grant in the IIS sense when all of the following hold:

• The investigator, not the company, originates the research question and writes the protocol.
• The investigator’s institution holds primary responsibility for IRB/ethics oversight, and where applicable, the regulatory filing (IND/IDE) or an approved exemption.
• The company’s role is limited to scientific/strategic review, a funding decision, and (if relevant) supply of its product — it does not direct study conduct, control the analysis, or hold approval rights over publication content beyond a standard pre-publication review period for confidentiality and accuracy.
• Funding is not conditioned on, and the company represents that it is not linked to, past or future purchasing/prescribing of the company’s products — a distinction most major IIS programs state explicitly in their public program descriptions, precisely because it is what keeps the grant on the research-funding side of the line rather than shading into an inducement.

If a company instead designs the protocol, selects the sites, and directs conduct through a CRO, the arrangement is trial sponsorship, not an investigator-initiated grant, regardless of what either party calls it.

Typical application process

Most major pharmaceutical and biopharmaceutical companies run a standing IIS program with a dedicated online portal, rather than accepting ad hoc proposals by email. The process generally follows a common shape across companies, though specific forms and timelines vary:

1. Concept or letter of intent. Many programs require a short concept proposal first, screening for strategic and scientific fit before a full application is invited.
2. Full application. A formal IIS application package — typically a structured proposal form, detailed budget, investigator CV(s) and licensure, and institutional information — submitted through the company’s grants portal.
3. Scientific and compliance review. The company reviews the proposal for scientific merit, alignment with its research interests, and compliance risk. This review is typically walled off from sales/marketing functions specifically to preserve the arm’s-length, non-promotional character of the grant.
4. Agreement execution. If approved, funding is conditional on execution of a grant agreement between the company and the investigator’s institution (not the individual investigator), covering budget, product supply if applicable, data/publication terms, and reporting obligations.
5. Conduct and reporting. The institution conducts the study under its own IRB and regulatory oversight, with periodic progress and financial reporting to the funder as specified in the agreement.

Review timelines are typically measured in weeks rather than the months common to federal grant cycles, and unlike federal award mechanisms, there is no unified cross-industry application format — each company’s IIS program has its own forms, portal, and review cadence, so institutional grants offices generally maintain company-specific guidance rather than a single template.

Disclosure and conflict-of-interest considerations

IIS funding is industry funding, which brings a distinct disclosure and conflict-of-interest (COI) profile compared with federal awards:

• Institutional and individual disclosure. Investigators generally must disclose the grant as an outside financial interest under their institution’s COI policy, separate from disclosing it to funders like NIH — industry research funding to an investigator’s institution can itself constitute a reportable financial relationship depending on the policy’s thresholds, even when the investigator receives no personal payment.
• Publication rights. IIS agreements typically preserve the investigator’s right to publish regardless of results, subject only to a defined pre-publication review window (commonly 30-60 days) for the company to check for confidential or proprietary information — not a right to block or alter unfavorable findings. This is a frequent negotiation point and a common point of institutional legal review before an agreement is signed.
• No sales linkage. Because funding decisions must be, and be seen to be, independent of sales and marketing, most programs firewall IIS review from commercial functions and publish that separation as part of their program terms.
• Public reporting. In the United States, payments and other transfers of value from applicable manufacturers to physicians and teaching hospitals — including many research payments — are subject to reporting under the federal Physician Payments Sunshine Act (part of the Affordable Care Act) and published via CMS’s Open Payments database, a disclosure channel that has no equivalent for federal grant funding.

Because both the funding relationship and the disclosure obligations differ from federal awards, institutions typically route IIS proposals through the same sponsored-programs office as other external funding, but flag them for an additional industry-specific COI review rather than treating the standard federal-award compliance checklist as sufficient on its own.

Related terms

See sponsor-investigator for the regulatory role an investigator takes on when running a company-funded study under their own IND/IDE, significant financial interest for how industry funding is disclosed under institutional and federal COI policy, and Sponsor vs. CRO for how company-directed trial sponsorship differs structurally from the investigator-initiated model described here.